Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 36

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 36
---
 need to expend significant resources to further establish and grow this
internal infrastructure and properly train sales personnel with respect to regulatory compliance matters. We may also choose to engage
or enter into other arrangements with third parties to provide sales and marketing services for us in place of or to supplement our internal
commercialization infrastructure. We may not be able to secure sales personnel or relationships with third-party sales organizations
that are adequate in number or expertise to successfully market and sell our proprietary formulations, drug products and pharmacy services.
Further, any third-party organizations we may seek to partner with or engage may not be able to provide sales and marketing services
in accordance with our expectations and standards, may be more expensive than we can afford or may not be available on otherwise acceptable
terms or at all. If we are unable to establish and maintain compliant and adequate sales and marketing capabilities, through our own
internal infrastructure or third-party services or other arrangements, we may be unable to sell our formulations, drug products or services
or generate meaningful revenues.

 23 

We depend upon consultants, outside contractors
and other third-party service providers for key aspects of our business.

We are substantially dependent
on consultants and other outside contractors and service providers for key aspects of our business. For instance, we rely upon pharmacist,
physician and research consultants and advisors to provide us with significant assistance in the evaluation of product development opportunities,
and we have engaged or supported, and expect to continue to engage or support, consultants, advisors, contract manufacturers, clinical
research organizations (“CROs”), and others to design, conduct, analyze and interpret the results of any clinical or non-clinical
trials or other studies in connection with the research and development of our products. If any of our consultants or other service providers
terminates its engagement with us, or if we are unable to engage highly qualified replacements as needed on commercially reasonable terms,
we may be unable to successfully execute our business plan. We must effectively manage these third-party service providers to ensure
that they successfully carry out their contractual obligations and meet expected deadlines. However, these third parties often engage
in other business activities and may not devote sufficient time and attention to our activities, and we may have only limited contractual
rights in connection with the conduct of the activities we have engaged the service providers to perform. If we are unable to effectively
manage our outsourced activities or if the quality, timeliness or accuracy of the services provided by third-party service providers
is compromised for any reason, our development activities may be extended